AstraZeneca (NYSE:AZN – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Saturday, Wall Street Zen reports.
Several other equities analysts also recently weighed in on AZN. CICC Research initiated coverage on AstraZeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 target price on the stock. Nordea Equity Research raised shares of AstraZeneca from a “sell” rating to a “buy” rating in a research note on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Zacks Research upgraded shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 13th. Finally, Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of $206.67.
View Our Latest Report on AstraZeneca
AstraZeneca Stock Up 6.9%
AZN stock opened at $186.49 on Friday. The company has a 50 day moving average price of $164.48 and a two-hundred day moving average price of $180.21. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. The stock has a market capitalization of $289.23 billion, a P/E ratio of 27.88, a PEG ratio of 1.35 and a beta of 0.27. AstraZeneca has a one year low of $153.41 and a one year high of $212.71.
AstraZeneca (NYSE:AZN – Get Free Report) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The company had revenue of $16.21 billion for the quarter, compared to analyst estimates of $16 billion. During the same quarter in the prior year, the company posted $2.38 EPS. The business’s revenue for the quarter was up 6.5% compared to the same quarter last year. As a group, sell-side analysts expect that AstraZeneca will post 10.21 EPS for the current year.
Hedge Funds Weigh In On AstraZeneca
Several hedge funds and other institutional investors have recently modified their holdings of the company. Aries Wealth Management boosted its stake in shares of AstraZeneca by 1.3% during the 3rd quarter. Aries Wealth Management now owns 4,546 shares of the company’s stock worth $741,000 after acquiring an additional 60 shares in the last quarter. Triumph Capital Management increased its stake in shares of AstraZeneca by 32.6% in the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after purchasing an additional 62 shares in the last quarter. Riversedge Advisors LLC raised its holdings in AstraZeneca by 2.9% in the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock worth $379,000 after purchasing an additional 67 shares during the period. Veery Capital LLC raised its holdings in AstraZeneca by 3.9% in the 3rd quarter. Veery Capital LLC now owns 1,857 shares of the company’s stock worth $300,000 after purchasing an additional 70 shares during the period. Finally, Obermeyer Wealth Partners boosted its position in AstraZeneca by 0.6% during the third quarter. Obermeyer Wealth Partners now owns 11,705 shares of the company’s stock worth $1,905,000 after purchasing an additional 70 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.
Trending Headlines about AstraZeneca
Here are the key news stories impacting AstraZeneca this week:
- Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
- Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
- Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
- Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
- Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
- Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance
AstraZeneca Company Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.
AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Featured Stories
- Five stocks we like better than AstraZeneca
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
